A detailed history of Graham Capital Management, L.P. transactions in Theravance Biopharma, Inc. stock. As of the latest transaction made, Graham Capital Management, L.P. holds 30,756 shares of TBPH stock, worth $302,946. This represents 0.01% of its overall portfolio holdings.

Number of Shares
30,756
Previous 28,559 7.69%
Holding current value
$302,946
Previous $242,000 2.07%
% of portfolio
0.01%
Previous 0.01%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$7.66 - $10.25 $16,829 - $22,519
2,197 Added 7.69%
30,756 $247,000
Q2 2024

Aug 14, 2024

BUY
$8.29 - $9.92 $101,187 - $121,083
12,206 Added 74.64%
28,559 $242,000
Q1 2024

May 15, 2024

BUY
$8.22 - $11.59 $134,421 - $189,531
16,353 New
16,353 $146,000
Q2 2023

Aug 14, 2023

SELL
$10.16 - $11.92 $33,202 - $38,954
-3,268 Reduced 18.23%
14,662 $151,000
Q1 2023

May 15, 2023

BUY
$9.87 - $11.44 $176,969 - $205,119
17,930 New
17,930 $194,000

Others Institutions Holding TBPH

About Theravance Biopharma, Inc.


  • Ticker TBPH
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 66,782,400
  • Market Cap $658M
  • Description
  • Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States, Europe, and Asia. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist used for the treatment of chronic obstructive pulmonary disease (COPD). Its product portfolio also inc...
More about TBPH
Track This Portfolio

Track Graham Capital Management, L.P. Portfolio

Follow Graham Capital Management, L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Graham Capital Management, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Graham Capital Management, L.P. with notifications on news.